CoChat

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Open access
Gupta, Mamta, Hendrickson, Andrea E. Wahner, Yun, Seong Seok, Han, Jing Jing, Schneider, Paula A., Koh, Brian D., Stenson, Mary J., Wellik, Linda E., Shing, Jennifer C., Peterson, Kevin L., Flatten, Karen S., Hess, Allan D., Smith, B. Douglas, Karp, Judith E., Barr, Sharon, Witzig, Thomas E., Kaufmann, Scott H. · 2012 · Blood
Cited by 103

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027–induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027–induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, up-regulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-04-346601

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 103

Metadata

Authors
Gupta, M., Hendrickson, A. E. W., Yun, S. S., Han, J. J., Schneider, P. A., Koh, B. D., Stenson, M. J., Wellik, L. E., Shing, J. C., Peterson, K. L., Flatten, K. S., Hess, A. D., Smith, B. D., Karp, J. E., Barr, S., Witzig, T. E., & Kaufmann, S. H.
Venue
Blood
Published
2012-01-12
Volume
119
Issue
2
Pages
476-487
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2015973524
Cited by
103
References
8
FWCI
4.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. https://app.cochat.ai/papers/10.1182/blood-2011-04-346601
The paper
Gupta, M., Hendrickson, A. E. W., Yun, S. S., Han, J. J., Schneider, P. A., Koh, B. D., Stenson, M. J., Wellik, L. E., Shing, J. C., Peterson, K. L., Flatten, K. S., Hess, A. D., Smith, B. D., Karp, J. E., Barr, S., Witzig, T. E., & Kaufmann, S. H. (2012). Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. https://doi.org/10.1182/blood-2011-04-346601

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.